These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 26160838)

  • 21. Alginate microspheres encapsulating hox transcript antisense RNA siRNA regulate the Hedgehog-Gli1 pathway to alleviate epidermal growth factor receptor tyrosine kinase inhibitors resistance.
    Lu G; Zhong H; Gao J; Zhang Y
    J Biomater Appl; 2024 Mar; 38(8):877-889. PubMed ID: 38261797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
    Patel H; Pawara R; Surana S
    Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.
    Iderzorig T; Kellen J; Osude C; Singh S; Woodman JA; Garcia C; Puri N
    Biochem Biophys Res Commun; 2018 Feb; 496(2):770-777. PubMed ID: 29337056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells.
    Vad-Nielsen J; Gammelgaard KR; Daugaard TF; Nielsen AL
    Lung Cancer; 2019 Jun; 132():132-140. PubMed ID: 31097086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors.
    Ma G; Zhang J; Jiang H; Zhang N; Yin L; Li W; Zhou Q
    Oncotarget; 2017 Nov; 8(59):99429-99437. PubMed ID: 29245913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.
    Xiao Y; Yin C; Wang Y; Lv H; Wang W; Huang Y; Perez-Losada J; Snijders AM; Mao JH; Zhang P
    Mol Oncol; 2018 Jun; 12(6):883-895. PubMed ID: 29633504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab effectively reverses Tyrosine kinase inhibitors (TKIs) resistance through inhibiting the accumulation of rictor on mitochondria-associated ER-membrane (MAM).
    Xu ZH; Liu CH; Hang JB; Gao BL; Hu JA
    Cancer Biomark; 2017 Dec; 20(4):581-588. PubMed ID: 28946557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR-TKI-induced HSP70 degradation and BER suppression facilitate the occurrence of the EGFR T790 M resistant mutation in lung cancer cells.
    Cao X; Zhou Y; Sun H; Xu M; Bi X; Zhao Z; Shen B; Wan F; Hong Z; Lan L; Luo L; Guo Z; Yin Z
    Cancer Lett; 2018 Jun; 424():84-96. PubMed ID: 29524558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenic drivers in nonsmall cell lung cancer and resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
    Pathak A; Rajappa S; Gore A
    Indian J Cancer; 2017 Dec; 54(Supplement):S1-S8. PubMed ID: 29292702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Makino A; Miyazaki A; Tomoike A; Kimura H; Arimitsu K; Hirata M; Ohmomo Y; Nishii R; Okazawa H; Kiyono Y; Ono M; Saji H
    Bioorg Med Chem; 2018 May; 26(8):1609-1613. PubMed ID: 29478801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.
    Galvani E; Sun J; Leon LG; Sciarrillo R; Narayan RS; Sjin RT; Lee K; Ohashi K; Heideman DA; Alfieri RR; Heynen GJ; Bernards R; Smit EF; Pao W; Peters GJ; Giovannetti E
    Oncotarget; 2015 Dec; 6(40):42717-32. PubMed ID: 26015408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.
    Bertran-Alamillo J; Cattan V; Schoumacher M; Codony-Servat J; Giménez-Capitán A; Cantero F; Burbridge M; Rodríguez S; Teixidó C; Roman R; Castellví J; García-Román S; Codony-Servat C; Viteri S; Cardona AF; Karachaliou N; Rosell R; Molina-Vila MA
    Nat Commun; 2019 Apr; 10(1):1812. PubMed ID: 31000705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation.
    Park SE; Kim DE; Kim MJ; Lee JS; Rho JK; Jeong SY; Choi EK; Kim CS; Hwang JJ
    Oncol Rep; 2019 Jan; 41(1):525-533. PubMed ID: 30365122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.
    Hidayat M; Mitsuishi Y; Takahashi F; Tajima K; Yae T; Miyahara K; Hayakawa D; Winardi W; Ihara H; Koinuma Y; Wirawan A; Nurwidya F; Kato M; Kobayashi I; Sasaki S; Takamochi K; Hayashi T; Suehara Y; Moriyama M; Moriyama H; Habu S; Takahashi K
    Bosn J Basic Med Sci; 2019 Nov; 19(4):355-367. PubMed ID: 31202256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
    Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
    Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigallocatechin gallate circumvents drug-induced resistance in non-small-cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis.
    Zhou Y; Huang S; Guo Y; Ran M; Shan W; Chen WH; Tam KY
    Phytother Res; 2023 Dec; 37(12):5837-5853. PubMed ID: 37621136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.
    Singleton KR; Hinz TK; Kleczko EK; Marek LA; Kwak J; Harp T; Kim J; Tan AC; Heasley LE
    Cancer Res; 2015 Oct; 75(20):4398-406. PubMed ID: 26359452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Advances in Long Non-coding RNAs on Resistant to EGFR-TKIs 
in Non-small Cell Lung Cancer].
    Li S; Yu H; Zhang G
    Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):121-128. PubMed ID: 29526180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer.
    Bronte G; Bravaccini S; Bronte E; Burgio MA; Rolfo C; Delmonte A; Crinò L
    Biol Rev Camb Philos Soc; 2018 Nov; 93(4):1735-1746. PubMed ID: 29671943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer.
    Suda K; Murakami I; Yu H; Kim J; Tan AC; Mizuuchi H; Rozeboom L; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    Mol Cancer Ther; 2018 Oct; 17(10):2257-2265. PubMed ID: 30049789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.